Most Liquid NASDAQ Health Care Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1GEHC GE HealthCare Technologies
1.51 B
 0.04 
 1.27 
 0.04 
2AVBP ArriVent BioPharma, Common
128.72 M
 0.18 
 3.60 
 0.64 
3APGE Apogee Therapeutics, Common
108.08 M
 0.17 
 3.27 
 0.55 
4AMGN Amgen Inc
11.48 B
 0.01 
 1.17 
 0.01 
5ISRG Intuitive Surgical
4.32 B
 0.13 
 1.69 
 0.22 
6ARGX argenx NV ADR
2.6 B
 0.11 
 1.85 
 0.21 
7ALNY Alnylam Pharmaceuticals
2.27 B
 0.06 
 2.08 
 0.12 
8AZTA Azenta Inc
2.18 B
(0.06)
 2.26 
(0.13)
9SRPT Sarepta Therapeutics
2.07 B
(0.11)
 1.68 
(0.18)
10IONS Ionis Pharmaceuticals
2.04 B
(0.11)
 2.40 
(0.27)
11ROIV Roivant Sciences
1.94 B
 0.04 
 1.48 
 0.06 
12SAGE Sage Therapeutic
1.51 B
(0.06)
 4.51 
(0.27)
13RPRX Royalty Pharma Plc
1.47 B
 0.00 
 1.07 
 0.00 
14ARVN Arvinas
1.27 B
 0.11 
 2.83 
 0.30 
15ALGN Align Technology
1.09 B
 0.03 
 2.39 
 0.06 
16BEAM Beam Therapeutics
1.09 B
 0.12 
 4.04 
 0.50 
17RLAY Relay Therapeutics
1.05 B
 0.02 
 7.71 
 0.17 
18ASTH Astrana Health
308.5 M
 0.02 
 3.41 
 0.07 
19MURA Mural Oncology plc
284.39 M
 0.09 
 2.77 
 0.25 
20SYRE Spyre Therapeutics
198.34 M
 0.23 
 3.51 
 0.80 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).